Miguel-Angel Perales, MD, and Caron A. Jacobson, MD, share insights regarding the context and implications of the recent actions by the FDA to add boxed warnings to CAR T-cell therapies.
Caron A. Jacobson, MD, and Miguel-Angel Perales, MD, look at both the regulatory and clinical components that will shape future research and utilization of CAR T-cell therapy in oncology and beyond.
Caron A. Jacobson, MD, and Miguel-Angel Perales, MD, discuss different uses for CAR T-cell therapy, particularly a trial in which a CAR T-Cell therapy is being evaluated in MRD-positive patients treated with chemotherapy.
Thought leaders discuss patient scenarios and different factors to consider when deciding how to select and utilize bridging therapy in the management of patients with LBCL.
Caron A. Jacobson, MD, and Miguel-Angel Perales, MD, review the impact of real-world analysis and how they may shape guidelines and clinical approaches with respect to the use of CAR T-cell therapy in LBCL.In particular, they note how continued research bolsters the safety profile of these agents.